British journal of neurosurgery · 2026
Sustained survival of a physician with recurrent choroid plexus papilloma using stereotactic radiosurgery and bevacizumab: a case report and literature review.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hoang Andrew, Diamandi Julia, Wei Chris Z, Thompson B Gregory, Kulich Scott, Gerszten Peter C, Hadjipanayis Constantinos G, Niranjan Ajay, Lunsford L Dade
Аннотация
PURPOSE: Choroid plexus papillomas (CPP) are most often benign intracranial tumors that present with hydrocephalus and increased intracranial pressure. We report the long-term management of a practicing anesthesiologist who developed neuraxis leptomeningeal spread of recurrent tumor eight years after initial surgical resection of a cerebellopontine angle tumor.
METHODS: Over a 20-year interval, thirteen stereotactic radiosurgery (SRS) procedures and spinal radiation therapy were performed for 32 recurrent tumor implants scattered in the brain and spine, with radiosurgical treatment beginning eight years after the primary surgery. In the last 36 months of life, bevacizumab immunotherapy was added.
RESULTS/CONCLUSION: He continued to practice medicine until neurological deficits developed during the last six months of life, following a prolonged period of disease stability.
METHODS: Over a 20-year interval, thirteen stereotactic radiosurgery (SRS) procedures and spinal radiation therapy were performed for 32 recurrent tumor implants scattered in the brain and spine, with radiosurgical treatment beginning eight years after the primary surgery. In the last 36 months of life, bevacizumab immunotherapy was added.
RESULTS/CONCLUSION: He continued to practice medicine until neurological deficits developed during the last six months of life, following a prolonged period of disease stability.